Quantifying cardiovascular disease risk factors in patients with psoriasis: a meta‐analysis. (December 2013)

• Record Type: Journal Article
• Authors: Miller, I.M.; Skaaby, T.; Ellervik, C.; Jemec, G.B.E.
• Is Part Of: British journal of dermatology. Volume 169:Number 6(2013:Dec.)
• Page Start: 1180
• Page End: 1187
• Publication Date: 2013-12
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/bjd.12490
• Languages: English
• ISSNs: 0007-0963

Abstract

<abstract abstract-type="main" id="bjd12490-abs-0001"> <title>Summary</title> <sec id="bjd12490-sec-0001" sec-type="section"> <title>Background</title> <p>In a previous meta‐analysis on categorical data we found an association between psoriasis and cardiovascular disease and associated risk factors.</p> </sec> <sec id="bjd12490-sec-0002" sec-type="section"> <title>Objectives</title> <p>To quantify the level of cardiovascular disease risk factors in order to provide additional data for the clinical management of the increased risk.</p> </sec> <sec id="bjd12490-sec-0003" sec-type="section"> <title>Methods</title> <p>This was a meta‐analysis of observational studies with continuous outcome using random‐effects statistics. A systematic search of studies published before 25 October 2012 was conducted using the databases Medline, EMBASE, International Pharmaceutical Abstracts, PASCAL and BIOSIS.</p> </sec> <sec id="bjd12490-sec-0004" sec-type="section"> <title>Results</title> <p>We included 59 studies with up to 18 666 cases and 50 724 controls. Psoriasis cases had a higher total cholesterol [weighted mean difference 8·83 mg dL<sup>−1</sup>, 95% confidence interval (CI) 2·94–14·72, <italic>P </italic>=<italic> </italic>0·003 (= 0·23 mmol L<sup>−1</sup>)], higher low‐density lipoprotein cholesterol [9·90 mg dL<sup>−1</sup>, 95% CI 1·56–18·20, <italic>P </italic>=<italic> </italic>0·020 (= 0·25 mmol L<sup>−1</sup>)], higher triglyceride [16·32 mg dL<sup>−1</sup>, 95% CI 12·02–20·63, <italic>P </italic><<italic> </italic>0·001 (= 0·18 mmol L<sup>−1</sup>)], a higher systolic blood pressure (4·77 mmHg, 95% CI 1·62–7·92, <italic>P </italic>=<italic> </italic>0·003), a higher diastolic blood pressure (2·99 mmHg, 95% CI 0·60–5·38, <italic>P </italic>=<italic> </italic>0·014), higher body mass index (0·73 kg m<sup>−2</sup>, 95% CI 0·37–1·09, <italic>P </italic><<italic> </italic>0·001), higher waist circumference (3·61 cm, 95% CI 2·12–5·10, <italic>P </italic><<italic> </italic>0·001), higher fasting glucose [3·52 mg dL<sup>−1</sup>, 95% CI 0·64–6·41, <italic>P </italic>=<italic> </italic>0·017 (= 0·20 mmol L<sup>−1</sup>)], higher nonfasting glucose [11·70 mg dL<sup>−1</sup>, 95% CI 11·24–12·15, <italic>P </italic><<italic> </italic>0·001 (= 0·65 mmol L<sup>−1</sup>)] and a higher HbA1c [1·09 mmol mol<sup>−1</sup>, 95% CI 0·87–1·31, <italic>P </italic><<italic> </italic>0·001 (= 2·2%)].</p> </sec> <sec id="bjd12490-sec-0005" sec-type="section"> <title>Conclusions</title> <p>From a preventive medicine perspective, the weighted mean differences between cases and controls are significant, and therefore relevant to the clinical management of patients with psoriasis.</p> </sec> </abstract>